Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495360 | 1.00 | MAOB (0.59) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL12194365 | 1.00 | MAOB (0.59) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL2498879 | 0.84 | MAOB (0.67) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL2498872 | 0.84 | MAOB (0.67) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL2503352 | 0.81 | MAOB (0.69) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL30412034 | 0.78 | MAOB (0.73) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL976424 | 0.78 | MAOB (0.73) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL2498876 | 0.78 | MAOB (0.64) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL9019897 | 0.76 | MAOB (0.69) | MAOBNR4A2SMPD1PTPN1SRD5A2 | |
| SCHEMBL1122805 | 0.76 | MRGPRX4 (0.71) | MAOBNR4A2SMPD1PTPN1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | MAOB 2736/4885NR4A2 43/4885SMPD1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.